AION Labs, the first-of-its-kind venture studio today (January 8) announced its new partnership with Amiti Ventures, a leading early-stage venture capital firm in Israel.
Digital health companies raked in more than $9.5bn as part of 698 global venture capital deals last year – with data analytics and mHealth apps leading the pack among the top-funded categories.
Massachusetts biopharma companies received $2.9bn in venture capital investment in 2016 – and as pressure continues to accelerate the drug development process, manufacturers will continue to turn to CROs and CMOs, says MassBio.
QuintilesIMS next week will officially be rebranded as IQVIA – the newest name in the “Mega-CRO” category created by the rapid and ubiquitous consolidation of the industry.
Outsourcing companies are expected to witness “significant investments” from private equity and venture capital, despite decreasing investment in the overall healthcare industry.
inVentiv Health announced last week that it has closed its previously announced transaction agreement with the private equity firm, Advent International.
The biopharmaceutical industry broke several records in 2015 – but to continue the trend will require a sustained investment from multiple stakeholders.
Catalent says it is contemplating expanding its Wisconsin single-use biologics facility as strong demand from SMEs and biotechs has almost filled current capacity.
The UK’s BioCity in Nottingham is adding a £30m ($47m) facility to house life science start-ups including CROs. The site will also become a hunting ground for a soon-to-launch venture capital fund which will invest in the SME tenants.
Biogen Idec, GlaxoSmithKline, Johnson & Johnson, Lilly and Pfizer have all committed to investing in the $100m venture capital fund, alongside Alzheimer’s Research UK and the UK government.
Pharma companies have called on the Swedish government to prevent manufacturing going the way of R&D and leaving the country, after AstraZeneca closed its research in Lund in 2012.
Ricerca Biosciences has been bought by private equity group Main Market Partners in a deal that means the contract research organisation's (CRO) 199 employees keep their jobs.
Investors only back drug innovators because they have to according to Index Venture Management's Kevin Johnson, who says less risky 'first to be second' firms are actually much more attractive.
An under-attended investor day at Quintiles, the world’s largest CRO, is indicative of waning interest in the clinical sector according to a William Blair analyst.
Packaging Coordinators Inc (PCI) has announced its acquisition of Welsh contract development and manufacturing organisation (CDMO) Penn Pharmaceutical Services in a £127m ($215m) deal.
Lonza saw profits and capacity utilisation improve in the first half of 2014 with new pharma and biopharma supply contracts and ongoing restructuring being the key drivers.
CRO financial results season begins this week amid reports PPD could be sold, with other service providers and private equity viewed as potential bidders.
US contract research organisation (CRO) QPS has been called in by the Taiwanese Development Center for Biotechnology (DCB) to provide support services for biotech firms operating in the region.
Emerging markets, headed by China and India are tipped
to remain hot destinations for venture capital (VC)
investments this year, according to a recent survey by KPMG.
New UK Government proposals to scrap Capital Gains Tax (CGT) relief
will stifle life science innovation, according to a group of
biotech small and medium enterprises (SMEs).
According to new data, venture capital funding is on a downswing
with a demand for acquisitions shifting in the pharmaceutical
sector. The news could signal a trend towards the acquisition of
compounds, rights, licenses and product...
A new survey has revealed that venture capital investment in health
care ventures rarely goes beyond the money bestowed, and claims
that VCs add value through their expertise are rarely if ever
fulfilled.
Senior executives at LGC, a UK-headquartered provider of
pharmaceutical reference materials and analytical and diagnostic
services, are gearing up for a secondary buyout that will help it
to accelerate its expansion into international...
Abingworth Management, a UK venture capital group, has raised a
$350 million investment vehicle in a move that lends further weight
to suggestions that the funding crisis hitting the biotechnology
sector may be nearing its end.
The addition of HarbourVest Partner to Israeli life sciences
venture capital fund Vitalife prompted the fund to announce on
Monday the closing of its first fund, worth €46 million.
Venture capital investments in biotechnology and medical device
companies combined to total $4.7 billion (€4.4bn) in 2002, or 22
per cent of all investing, representing the highest proportion in
seven years, according to the MoneyTree...
